Attovia director Royston Aaron files Form 3

Attovia Therapeutics, Inc. director Royston Aaron filed an initial ownership report on Form 3.

Accepted by SEC EDGAR 08/04/2026 - 07:34 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Attovia Therapeutics, Inc. director Royston Aaron filed an initial ownership report on Form 3. The filing lists his status as a director but does not report any equity transactions or current holdings, and no Rule 10b5-1 trading plan is indicated.

Key Figures

Buy transactions: 0 Sell transactions: 0 Holding entries: 0

3 metrics

Buy transactions 0 buyCount in transactionSummary

Sell transactions 0 sellCount in transactionSummary

Holding entries 0 holdingEntries in transactionSummary indicating no reported positions

Key Terms

Form 3, transactionSummary, beneficial ownership

3 terms

Form 3 regulatory

"INSIDER FILING DATA (Form 3)"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

transactionSummary financial

""transactionSummary": {"buyCount": 0, "sellCount": 0"

beneficial ownership financial

"initial statement of beneficial ownership"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Attovia Therapeutics (ATTO) disclose in Royston Aaron's Form 3?

The Form 3 identifies Royston Aaron as a director of Attovia Therapeutics, Inc. It reports no equity transactions, no current holdings and no Rule 10b5-1 trading plan, serving as an initial statement of beneficial ownership.

Does the ATTO Form 3 for Royston Aaron report any share transactions?

No. The Form 3 shows no reported transactions, with buyCount, sellCount, acquireCount and disposeCount all at 0. It is purely an initial ownership filing without any purchase, sale or derivative exercise activity.

Are any Attovia Therapeutics (ATTO) shares or options reported as held by Royston Aaron?

No current positions are shown. The filing’s transactionSummary indicates holdingEntries: 0 and derivativeSummary is empty, so no common stock or derivative securities are reported as held in this Form 3.

Is there any 10b5-1 trading plan associated with this ATTO Form 3 filing?

No. The Form 3 data show aff_10b5_one: null, and there is no footnote disclosure of a Rule 10b5-1 plan. The filing therefore does not state that any transactions are under a pre-arranged trading plan.

What insider role is confirmed for Royston Aaron at Attovia Therapeutics (ATTO)?

The Form 3 confirms that Royston Aaron is a director of Attovia Therapeutics, Inc., with is_director recorded as 1 and is_officer and is_ten_percent_owner both recorded as 0, indicating director status only.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Royston Aaron

(Last) (First) (Middle)

C/O ATTOVIA THERAPEUTICS, INC.

1091 INDUSTRIAL ROAD, SUITE 310

(Street)

SAN CARLOS CALIFORNIA 94070

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
08/04/2026

3. Issuer Name and Ticker or Trading Symbol
Attovia Therapeutics, Inc. [ ATTO ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Steven Chan , Attorney-in-Fact	08/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)